OXiGENE to raise $10 million in private placement
OXiGENE, Inc., a US-based biopharmaceutical company that develops therapeutics to treat cancer and eye diseases, is plans to raise approximately $10 million in gross proceeds.
Each unit would consist of one share of common stock and two warrants with different clauses attached. One of the warrants is exercisable for five years to purchase 0.45 shares of common stock at an exercise price of $2.10 per share of common stock. The other warrant is exercisable during a period beginning on the date of issue and ending on a date which is the later of nine months from the date of issuance or ten trading days after the earlier of the public announcement of the outcome of the planned interim analysis by the Independent Data Safety Monitoring Committee of data from the company’s Phase II/III pivotal clinical trial regarding ZYBRESTAT as a treatment for anaplastic thyroid cancer or a public announcement of future plans for the clinical trial, as specified in the form of warrant. The second warrant allows the holder to purchase 0.45 shares of common stock at an exercise price of $1.60 per share.
PPM is the leading U.S. entrepreneurial firm that specializes in writing private placement memorandums (PPM) and linking investors with entrepreneurs.
Since 1999, the founders of PPM have provided professional business writing services, such as a PPM or business plan, to more than 2,000 businesses worldwide. Our company is considered to be the most cost effective, efficient consultants for private placement memorandum development in the United States. We are Wall Street’s, and by extension, the New York private placement (PPM) leaders.
PPM.co’s main service is the creation of private placement memorandum regulation d (Reg. d) documents. However, we offer much more. In case the entrepreneur needs additional services, such as a business plan, website, or additional legal work, PPM can create one pricing package for all required documentation or service. Because we simultaneously work with many companies both in and out of the U.S., the ability to adapt to the individual needs – as well as to regional and global demands – helps our clients save needed capital and time.
We are leaders in:
• New York Private Placement
• Biotech Private Placement
• Technology Private Placement
• Debt Private Placement
• Equity Private Placement
• Technology Private Placement Memorandum Writing
• New York Private Placement Memorandum Writing
• Biotechnology Private Placement Memorandum Writing
• Debt Private Placement Memorandum Writing
• Equity Private Placement Memorandum Writing